Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ; h& k- w4 v J
: @& g3 v* X7 M! B+ u% Z: k5 @$ p
: @, b; }2 _3 o* r% `
Sub-category:
- y2 u+ a& }, yMolecular Targets
% L; t" ]2 h8 K9 L- t! @2 R( ~" V7 t4 x$ ^ h
6 G! s! |6 a2 n+ l. D
Category:% c D4 o; r; Y, O: Q
Tumor Biology 0 | l7 ~4 D" ^+ h
" a" p2 \5 Y# k, a5 N9 x
% N: l5 ^, Y1 Y' K1 F
Meeting:
# o8 t+ p; W7 g; {# E2011 ASCO Annual Meeting
% g% J. \; f# g2 g& e" J, [( g+ L7 J: l. ?
2 X9 F: q" L- G- l: {% lSession Type and Session Title:$ w' p$ y4 F% K# E3 ~& O% t
Poster Discussion Session, Tumor Biology
' V1 E" ~4 }+ j, u+ r
9 I9 a5 s; O1 f# f/ Q; U) I
% y' b$ E' @3 o+ DAbstract No:3 B! Q: s4 u1 _1 e) c/ ` N
10517
V5 ^5 Y& I$ V4 `9 w
( r/ ~3 Y/ l) U3 V# W1 U6 y! W D: c( N a
Citation:/ _% _6 E6 \+ b, q6 F$ A* `
J Clin Oncol 29: 2011 (suppl; abstr 10517)
) x, d: k( m4 A+ y) A( T$ m X3 s7 H' y* H& y
, K9 M# S& O2 X% s* _Author(s):: L+ E; Q7 ?% n6 d' ~
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
/ o, T) j: }! k3 G+ j) H( n
# m5 q7 y; W, A: B9 h3 z& ^! Q% X4 s, V
$ b" ^& _$ o4 u
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
p/ d$ m- C2 N5 |
0 O: a* i6 x6 C( S* iAbstract Disclosures
. w* Z4 i1 q( b4 t8 B% V3 K
4 H1 N" c- E$ W0 s& T& IAbstract:
5 N1 R7 } t1 j, \ Q. F
& u% g* x' x; J) w
" p; N. q! n+ j& g6 zBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 \# I! b; X6 m' h& r" a; P( U' N& i( P& { n2 P: I' G7 k0 Y
8 v# _6 m, C8 p% i; r5 h) b: N3 y0 [; X* v |
请教下 3a 术后 检查
请教下 3a 术后 检查快两年了， 验血 不是每次都是 肿标 5项吗，我的复查 好像 有时
30岁教师确诊肺癌后逆袭：手术后，我
讲述者：范菇娘整理者：pear编者按“用实力坚持到胜利”ALK阳性非小细胞肺癌患者摄影
求助：1a1实体型低分化alk突变复发概
背景：35岁男性，无吸烟史，有熬夜习惯，检查前曾参与新房装修。24年7月底体检第一次
求助：肺腺癌晚期，奥希30个月耐药，
父亲65岁：
23年1月份：持续咳嗽，医院CT后，左肺大量胸腔积液，确诊肺腺癌晚期，胸膜
母亲晚期肺癌跨越13年，这是我家长期
讲述者：不怕辣椒不怕癌整理者：雪漓
在我家抗癌跨越10年之际，鹰版就曾邀请我写一篇
显身卡
